Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
Andrew H. Wei,
Gail J. Roboz,
Herve Dombret,
Hartmut Dohner,
Andre C. Schuh,
Pau Montesinos,
Dominik Selleslag,
Sergey N. Bondarenko,
Thomas Prebet,
Yinzhi Lai,
Barry Skikne,
C.L. Beach,
Farhad Ravandi
Affiliations
Andrew H. Wei
Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne
Gail J. Roboz
Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, New York, NY
Herve Dombret
Hematology, Hopital Saint-Louis, Assistance Publique – Hopitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Universite Paris Cite, Paris
Hartmut Dohner
Department of Internal Medicine III, Ulm University Hospital, Ulm
Andre C. Schuh
Princess Margaret Cancer Centre, Toronto, ON
Pau Montesinos
Hospital Universitario y Politecnico La Fe, Valencia
Dominik Selleslag
AZ Sint-Jan Brugge-Oostende AV, Bruges
Sergey N. Bondarenko
RM Gorbacheva Research Institute, Pavlov University, St. Petersburg
Thomas Prebet
Bristol Myers Squibb, Summit, NJ
Yinzhi Lai
Bristol Myers Squibb, Summit, NJ
Barry Skikne
Bristol Myers Squibb, Summit, NJ, USA; University of Kansas Cancer Center, Kansas City, KS
C.L. Beach
Bristol Myers Squibb, Summit, NJ
Farhad Ravandi
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
